Consequently, a risperidone-treated CYP2D6 IM patient with renal failure, where both risperidone and paliperidone are accumulated, obtains a substantially larger effect on the exposure of active moiety than predicted from the CYP2D6 genotype itself. This evidence concerns the gene CYP2D6 and kidney failure.